Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan.

What Was Tested

The paper reports a study of Lisinopril and Losartan, published as a randomized controlled trial.

The goal of this study was to compare myocardial perfusion reserve (MPR) before and after long-term treatment with lisinopril and losartan in patients with hypertension and left ventricular hypertrophy (LVH).

Who Took Part

The abstract describes 17 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The researchers measured pre- and post-treatment myocardial blood flow (MBF) by positron emission tomography in 17 patients (lisinopril: 9 patients, losartan: 8 patients) with hypertension and LVH at baseline and after coronary vasodilation with intravenous dipyridamole.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Lisinopril and who got the comparison, which limits bias.

In addition, the researchers measured rest and hyperemic blood flow in eight normotensive controls.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Coronary Circulation, Heart Ventricles, Hypertension and Hypertrophy, Left Ventricular.

What This Means in Plain Language

The paper is a randomized study of Lisinopril and Losartan in 17 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2002 (Journal of the American College of Cardiology), a journal based in United States.

More context: all human trials.